AskMed

Pulmonary Thrombosis: Causes, Diagnosis and Risk Classes

Pulmonary thrombosis means a blood clot blocking one or more of the pulmonary arteries, the vessels that carry blood from the heart to the lungs. In most people the clot did not start there: it formed in a deep vein, usually in the leg, broke loose and travelled to the lungs, which is why doctors usually call it pulmonary embolism (PE) and group it with deep vein thrombosis (DVT) as venous thromboembolism (VTE). Less often the clot forms inside the lung arteries themselves, which is called in situ thrombosis. This guide explains both routes, Virchow's triad of clot causes, the risk factors that guidelines rank as strong, moderate or weak, and how doctors work up a suspected clot with probability scores, D-dimer, CT pulmonary angiography, lung scans and heart ultrasound. It then covers the severity classes, the main treatment classes and the long-term complication called chronic thromboembolic pulmonary hypertension. Every figure links to the guideline or study it comes from.

What does pulmonary thrombosis mean?

Pulmonary thrombosis is a blood clot, or thrombus, inside the pulmonary arteries, which carry blood from the right side of the heart to the lungs. The US National Heart, Lung, and Blood Institute (NHLBI) describes pulmonary embolism as an embolus from a deep vein blood clot, or from a blood vessel in the lungs, that breaks loose and travels to the lungs, so most clots in the lung arteries start in the deep veins of the legs or pelvis. Because the leg clot and the lung clot are one disease, guidelines treat them together as venous thromboembolism. The American Society of Hematology (ASH) puts its frequency at about 1 to 2 people per 1,000 each year, roughly 300,000 to 600,000 events a year in the United States. The 2019 European Society of Cardiology (ESC) guideline gives an annual pulmonary embolism incidence of 39 to 115 per 100,000 people and ranks venous thromboembolism as the third most frequent acute cardiovascular syndrome, after heart attack and stroke.

Embolism or a clot formed in place?

On a CT scan, a clot in the lung arteries shows up as a filling defect, a gap in the dye-filled vessel. A 2023 review in the American Journal of Roentgenology by Baranga and colleagues points out that such defects are commonly presumed to be emboli from distant veins, particularly leg DVT, but that growing evidence supports a second route: thrombosis that arises within the pulmonary arteries without any DVT. This in situ pulmonary arterial thrombosis is attributed to damage of the vessel lining, body-wide inflammation and acute lung injury, and it has been described in COVID-19, trauma, acute chest syndrome in sickle cell disease, lung infections and severe pulmonary arterial hypertension. The authors argue that telling the two apart may matter for treatment decisions and outcomes, although most guideline pathways still manage a clot in the lung arteries as pulmonary embolism.

Whatever its origin, a clot in the lung arteries can be dangerous. The NHS advises calling 999 (911 in the US) or going to an emergency department for sudden breathlessness, chest or upper back pain, a very fast heartbeat or collapse, and not driving yourself there. Coughing up blood also needs urgent medical advice.

How does a clot form? Virchow's triad explained

Virchow's triad is the classic explanation of how a clot forms in a vein: blood flow slows (stasis), the blood becomes more ready to clot (hypercoagulability), and the vessel wall is injured or inflamed. In a 2008 historical review in the British Journal of Haematology, Bagot and Arya note that the 19th-century pathologist Rudolf Virchow coined the terms thrombosis and embolism, but that the triad in its modern wording was only routinely credited to him about a hundred years after his work, once experiments had confirmed each factor. The 2015 Nature Reviews Disease Primers overview by Wolberg and colleagues states that a combination of blood stasis, plasma hypercoagulability and endothelial dysfunction is thought to trigger venous thrombosis, which starts most often in the valve pockets of large veins. The NHLBI explains each part: being still slows blood flow in the veins, surgery or injury can damage the vein lining, and conditions such as cancer, its treatments and kidney disease make the blood clot more easily.

Stasis: slow blood flow bed rest, long travel, after surgery Thrombosis Hypercoagulability cancer, hormones, pregnancy, thrombophilia Vessel wall injury surgery, trauma, inflammation, catheters
Virchow's triad, with examples from the NHLBI and the ESC 2019 risk factor table. Most risk factors act on more than one side.

The triad also helps explain the two routes into the lung arteries. A leg DVT usually grows where blood pools behind vein valves, so stasis is central, while in situ thrombosis in the lung is tied mainly to the vessel-wall side: damaged lining and inflammation, as the 2023 review describes. In real patients the factors pile up, and the NHLBI notes that the more risk factors a person has, the greater the chance of a clot.

What causes pulmonary thrombosis? Risk factors ranked

Pulmonary thrombosis is caused in most cases by a leg vein clot, and the ESC 2019 guideline ranks the risk factors for that clot by how much they raise the odds of venous thromboembolism. Strong risk factors, with an odds ratio above 10, include a broken leg, hip or knee replacement, major trauma, spinal cord injury, a previous clot, a hospital stay for heart failure or atrial fibrillation, and a heart attack, the last two within the past 3 months. Moderate risk factors, with odds ratios of 2 to 9, include cancer, with the highest risk in metastatic disease, chemotherapy, oral contraceptives, hormone replacement therapy, in vitro fertilisation, the period after childbirth, infection, inflammatory bowel disease, autoimmune disease, central venous lines, paralysis after a stroke and thrombophilia. Weak risk factors, with an odds ratio below 2, include bed rest for more than 3 days, long periods of sitting such as long travel, older age, obesity, diabetes, high blood pressure, varicose veins, laparoscopic surgery and pregnancy itself.

Age and family matter too. The NHLBI says the risk of venous thromboembolism nearly doubles every 10 years after age 40, and that brothers and sisters of someone with a clot have more than double the risk of the general population. Wolberg and colleagues list non-O blood groups and the factor V Leiden mutation among the genetic risk factors. Testing for inherited thrombophilia is not routine, though: the ASH 2023 thrombophilia guideline makes a strong recommendation against testing the general population before starting combined oral contraceptives, and suggests testing only in selected situations, such as a clot linked to a hormonal or non-surgical major transient risk factor, or a family history of antithrombin, protein C or protein S deficiency. Pregnancy brings its own numbers: in the ESC guideline, IVF was linked to a 4.22-fold higher hazard of venous thromboembolism in the first trimester, and thromboembolism caused 1.13 direct maternal deaths per 100,000 maternities in the UK and Ireland in 2013 to 2015. Before an operation, hospitals estimate a surgical patient's clot risk with tools such as the Caprini score calculator.

How do doctors estimate the probability of a lung clot?

Doctors estimate the probability of a lung clot before ordering tests because the right test depends on how likely the clot is, and the ASH 2018 diagnosis guideline builds every pathway on this pretest probability. The most used tool is the Wells rule, which Wells and colleagues published in Thrombosis and Haemostasis in 2000 from a regression on 40 clinical variables. It keeps seven: clinical signs of DVT (3 points), no alternative diagnosis (3), heart rate over 100 (1.5), immobilisation or surgery in the previous 4 weeks (1.5), a previous DVT or PE (1.5), coughing up blood (1) and cancer (1). A score under 2 means low probability, 2 to 6 moderate and over 6 high; in the two-level version, 4 or less means PE unlikely. In that paper, only 2.2% of PE-unlikely patients with a negative D-dimer had PE, a combination that covered 46% of patients. The ESC 2019 guideline also accepts the revised Geneva score, which uses its own items.

You can add up the points with the Wells score for PE calculator. When the question is a clot in the leg rather than the lung, the separate Wells score for DVT calculator applies.

PERC: ruling out without a blood test

For patients a doctor already judges to be at low risk, the pulmonary embolism rule-out criteria (PERC) can avoid even a D-dimer test. Kline and colleagues derived PERC in 2004 from 3,148 emergency department patients at 10 US hospitals. All eight criteria must be absent: age under 50, pulse under 100, oxygen saturation above 94%, no swelling of one leg, no coughing up blood, no recent trauma or surgery, no previous PE or DVT and no hormone use. In their low-risk validation group, PE was found in 1.4% of patients who met the rule, below the 1.8% test threshold they had calculated, but specificity was only 27%, so most people without PE still fail at least one criterion. The ESC 2019 guideline lists the same eight criteria. You can check them with the PERC rule calculator.

Which tests confirm or rule out pulmonary thrombosis?

The tests that confirm or rule out pulmonary thrombosis are chosen by clinical probability: a D-dimer blood test when PE is unlikely, and imaging, usually CT pulmonary angiography (CTPA), when PE is likely or the D-dimer is raised. D-dimer is a substance released when a clot breaks down, as the NHLBI explains. The ESC 2019 guideline gives the standard cut-off as 500 µg/L and allows an age-adjusted cut-off of age × 10 µg/L above age 50, notes that quantitative laboratory tests have a sensitivity of 95% or more, and warns that D-dimer cannot confirm PE, because many other conditions raise it. Point-of-care D-dimer tests have a sensitivity of about 88%, so the ESC limits them to patients with low probability. The ASH 2018 guideline reaches the same logic: with low pretest probability, starting with D-dimer reduces the need for imaging, while high probability calls for imaging straight away. The NHLBI calls CTPA the main test for diagnosing pulmonary embolism.

How well CTPA works depends on the starting probability. In the PIOPED II study cited by the ESC, CTPA had a sensitivity of 83% and a specificity of 96%, and a negative scan was correct in 96% of patients with low clinical probability, 89% with intermediate probability and only 60% with high probability. That is why the ESC treats a negative CTPA as enough to exclude PE in low or intermediate probability, but not always in high probability.

V/Q scan, echocardiography and leg ultrasound

A ventilation-perfusion (V/Q) scan compares air flow and blood flow in the lungs. The ESC puts its radiation dose at about 2 mSv, against 3 to 10 mSv for CTPA, and needs no iodine contrast, so it may be preferred in pregnancy, in young women, after a severe reaction to contrast and in severe kidney failure. A planar V/Q scan is inconclusive in about half of cases, while the SPECT version is non-diagnostic in under 3%. ASH calls V/Q scanning and CTPA the most validated tests for PE. An echocardiogram, an ultrasound of the heart, has a different job: in a patient in shock with suspected PE, the ESC says that no sign of strain on the right ventricle practically excludes PE as the cause, while clear right ventricular overload can justify emergency clot-clearing treatment when CT cannot be done at once. In stable patients its negative predictive value is only 40% to 50%, so a normal echo does not rule PE out. Compression ultrasound of the legs, which ASH names as the standard test for DVT, looks for the leg clot that most lung clots come from.

  1. Unstable (shock or low blood pressure): bedside echocardiogram and CTPA as soon as possible; managed as suspected high-risk PE.
  2. Stable: estimate clinical probability with the Wells or revised Geneva score; if probability is low, PERC may end the workup.
  3. Low or unlikely: D-dimer, age-adjusted after 50; a negative result excludes PE.
  4. Likely, or D-dimer raised: CTPA, or a V/Q scan when contrast or radiation is a concern.
  5. PE confirmed: severity class from PESI or sPESI, right ventricular imaging and troponin.
The usual order of the workup for suspected pulmonary embolism, from the ESC 2019 and ASH 2018 guidelines.

Each step has its own cut-offs, and the guidelines don't word them identically, which is where questions pile up during a real workup. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. Ask it whether a D-dimer of 620 µg/L rules out PE in a 68-year-old whose Wells score is 3, and it sets out the age-adjusted cut-off, what the ESC and ASH guidelines say about that probability level, and where each statement comes from, so you can read the exact wording yourself.

Check a D-dimer or Wells result against the guidelines:

How is severity classified once a clot is confirmed?

Once a clot is confirmed, the ESC 2019 guideline sorts pulmonary embolism into four risk classes by the chance of early death: high, intermediate-high, intermediate-low and low. High-risk PE means the circulation is failing: cardiac arrest, obstructive shock, or a systolic blood pressure below 90 mmHg, or a drop of 40 mmHg or more, lasting over 15 minutes, with signs that organs are not getting enough blood. For everyone else the ESC combines three things: a clinical score, the Pulmonary Embolism Severity Index (PESI) or its simplified version (sPESI); signs of right ventricular strain on echocardiography or CT; and a raised troponin, a marker of heart muscle stress. In the ESC tables, 30-day mortality runs from 0% to 1.6% in PESI class I to 10.0% to 24.5% in class V, and from 1.0% with an sPESI of 0 to 10.9% with an sPESI of 1 or more.

The class shapes where and how treatment happens. ASH 2020 suggests home treatment over hospital treatment for PE at low risk of complications, and CHEST 2021 recommends outpatient treatment for low-risk PE when the person can get the medicines, reach follow-up care and has suitable home circumstances. For intermediate-high risk, the ESC recommends close monitoring so that any worsening is caught early. You can score PESI and sPESI with the PESI score calculator.

How is pulmonary thrombosis treated?

Pulmonary thrombosis is treated mainly with anticoagulants, medicines often called blood thinners, which the NHS explains stop clots getting bigger and prevent new clots forming. The ESC 2019 guideline advises starting anticoagulation while tests are still under way when clinical probability is high or intermediate. For the main course, the guidelines favour direct oral anticoagulants (DOACs) over the older vitamin K antagonists: ESC prefers them for eligible patients, ASH 2020 suggests them, and CHEST 2021 makes a strong recommendation for them over vitamin K antagonists in the first 3 months. In the trials the ESC pooled, major bleeding occurred in 1.1% of patients on DOACs against 1.7% on vitamin K antagonists. Injected options, low-molecular-weight heparin, fondaparinux and unfractionated heparin, are used to start treatment or in special cases. All patients should be treated for at least 3 months, according to the ESC, and the NHS gives the same minimum.

Some groups need a different class. In pregnancy, the ESC calls low-molecular-weight heparin the treatment of choice because it does not cross the placenta, and says DOACs are contraindicated. For a clot linked to cancer, CHEST 2021 recommends an oral factor Xa inhibitor over low-molecular-weight heparin, with a caution about gut bleeding in cancers of the digestive tract. For confirmed antiphospholipid syndrome, CHEST suggests a vitamin K antagonist over a DOAC.

Clot-dissolving treatment and procedures

Thrombolysis, a clot-dissolving medicine given into a vein, is kept for the sickest patients. ASH 2020 makes a strong recommendation for thrombolysis followed by anticoagulation in PE with circulatory compromise, and CHEST 2021 suggests it for PE with low blood pressure when bleeding risk is not high. For PE with right ventricular strain but stable blood pressure, ASH suggests anticoagulation alone over routine thrombolysis, and CHEST recommends against systemic thrombolysis in most patients without low blood pressure. The reason is bleeding: in a meta-analysis cited by the ESC, severe bleeding occurred in 9.9% of patients given thrombolysis and bleeding inside the skull in 1.7%. When bleeding risk is high, thrombolysis has failed, or shock may cause death before it can work, CHEST suggests catheter-assisted clot removal where the expertise exists, and the ESC also covers surgical embolectomy. At the other end, for a small subsegmental clot with no leg DVT and a low risk of recurrence, CHEST suggests close clinical follow-up over anticoagulation.

How long treatment lasts

After the first 3 to 6 months, the question is whether to stop or continue. ASH 2020 suggests a primary course of 3 to 6 months rather than 6 to 12, then indefinite anticoagulation when the clot had no clear trigger or was provoked by a chronic risk factor, and it makes a strong recommendation for indefinite treatment after a second unprovoked clot. The ESC explains why the trigger matters: after treatment stops, recurrence was about 2.5% a year after PE with a transient risk factor, such as surgery, against 4.5% a year when no risk factor was found.

These choices depend on the person: kidney function, pregnancy, cancer type, bleeding risk and what triggered the clot. When you want to see how the guidelines compare on one of them, AskMed can put the ESC, ASH and CHEST positions side by side. Ask it, for example, which anticoagulant class each guideline prefers for a clot linked to bowel cancer, and why, and the answer links each recommendation to its guideline and year, so you can discuss the options with the treating team rather than change any treatment on your own.

Compare what ESC, ASH and CHEST say about a treatment question:

What is chronic thromboembolic pulmonary hypertension?

Chronic thromboembolic pulmonary hypertension (CTEPH) is a late complication in which clots in the lung arteries do not clear but persist as organised clots that narrow the vessels and raises the pressure the right side of the heart has to pump against. The ESC 2019 guideline calls it a potentially fatal late sequela of pulmonary embolism and puts its cumulative incidence at 0.1% to 9.1% in the first 2 years after a symptomatic PE, a wide range that reflects referral bias and how hard the condition is to diagnose. In a Swiss screening study it cites, the 2-year cumulative incidence was 0.79%. Milder long-term problems are much more common: between 20% and 75% of patients report worse health 6 months after PE, and in one cohort 47% had reduced aerobic capacity at 1 year. For this reason the ESC recommends a check 3 to 6 months after the acute episode for persisting breathlessness or reduced exercise capacity.

When CTEPH is suspected, the ESC names the planar V/Q scan as a suitable first imaging test, with a sensitivity of 96% to 97% and a specificity of 90% to 95%, and warns that CTPA should not be used on its own to exclude CTEPH. Most survivors don't need a repeat CT, because the lung arteries reopen in most patients. For operable CTEPH, surgery to remove the organised material, pulmonary endarterectomy, is the treatment of choice: in-hospital mortality can be as low as 4.7%, and 3-year survival was 89% in operated patients against 70% in those not operated. If you are still short of breath months after a PE, tell your doctor rather than putting it down to being unfit.

Frequently asked questions

Is pulmonary thrombosis the same as pulmonary embolism?

Mostly, yes. Both mean a clot in the lung arteries, and most such clots travel there from a leg vein, which is an embolism. A smaller group form in the lung arteries themselves, called in situ thrombosis, which has been described in COVID-19, trauma, sickle cell disease and severe pulmonary hypertension.

What is the most common cause of a clot in the lungs?

A deep vein thrombosis in the leg or pelvis that breaks loose. Strong triggers in the ESC 2019 guideline include hip or knee replacement, a broken leg, major trauma and a previous clot; cancer, hormones and the weeks after childbirth are moderate risk factors.

Can a normal D-dimer rule out pulmonary thrombosis?

Only when the clinical probability is low or PE is unlikely on a score such as Wells. With high probability, ASH advises going straight to imaging, usually CTPA, because a normal D-dimer is not reliable enough on its own.

How long are anticoagulants taken after a lung clot?

At least 3 months for everyone, according to the ESC 2019 guideline and the NHS. Treatment may continue indefinitely when the clot had no clear trigger, came back, or was linked to a lasting risk factor.

Can pulmonary thrombosis come back?

Yes. After anticoagulants stop, the ESC reports recurrence of about 2.5% a year when the clot followed a temporary trigger such as surgery, and about 4.5% a year when no trigger was found, which is why longer treatment is often suggested in the second group.

Sources

  1. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603.
  2. Lim W, Le Gal G, Bates SM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226-3256.
  3. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738.
  4. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023;7(22):7101-7138.
  5. Stevens SM, Woller SC, Baumann Kreuziger L, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545-e608.
  6. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(3):416-420.
  7. Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2(8):1247-1255.
  8. Baranga L, Khanuja S, Scott JA, et al. In Situ Pulmonary Arterial Thrombosis: Literature Review and Clinical Significance of a Distinct Entity. AJR Am J Roentgenol. 2023;221(1):57-68.
  9. Bagot CN, Arya R. Virchow and his triad: a question of attribution. Br J Haematol. 2008;143(2):180-190.
  10. Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. Nat Rev Dis Primers. 2015;1:15006.
  11. National Heart, Lung, and Blood Institute. Venous Thromboembolism: Causes and Risk Factors and Diagnosis.
  12. NHS. Pulmonary embolism.

Cited medical answers
you can trust.

AskMed on iPhone, iPad, Android and the web.